Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
CVS · against 27 other Healthcare companies of similar size
Ranked #13 of 28 · scores higher than 56% of peers
Bars: peers in each 10-point band of the valuation score5 peers with a valuation score of 70–79, including CVS · Click a bar to see the companies
Mainly thanks to its free cash flow yield, EBITDA yield and earnings yield, which are stronger than most Healthcare peers.
| Metric | CVS | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 27 reported | 4.2% | 4.1% | 58% | 30% | |
| EBITDA yieldHigher is better · 29 reported | 9.3% | 7.1% | 64% | 50% | |
| Free cash flow yieldHigher is better · 25 reported | 10.1% | 5.3% | 96% | 20% | |
| Book yieldHigher is better · 27 reported | 68.2% | 22.3% | 92% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 177.5B USD | 92 | 71 | |
| 2 | 78.1B USD | 89 | 60 | |
| 3 | 108.6B USD | 88 | 66 | |
| 4 | 97.5B USD | 87 | 67 | |
| 5 | 126.1B USD | 83 | 62 | |
| 9 | 89.7B USD | 76 | 50 | |
| 10 | 63.0B USD | 74 | 65 | |
| 11 | 534.1B HKD (≈$68.4B) | 72 | 75 | |
| 12 | 11.26T JPY (≈$76.6B) | 71 | 72 | |
| 13 | 116.9B USD | 70 | 47 | |
| 14 | 64.8B EUR (≈$71.3B) | 67 | 51 | |
| 15 | 171.0B USD | 66 | 45 | |
| 16 | 116.5B USD | 63 | 57 | |
| 17 | 84.5B EUR (≈$92.9B) | 62 | 51 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score